海外の治験の状況「1」での検索結果
7748件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- Primary intervention with mucosal insulin for prevention of type one diabetes in infants at high genetic risk to develop diabetes
- Type 1 diabetes-associated development of autoimmunity Nutritional, Metabolic, Endocrine Insulin dependent diabetes mellitus
- Austria, Germany, Italy, Switzerland, United Kingdom, United States of America
- 2007-03-01
Not Recruiting
- Brief Intervention for Type 1 diabetes: Education for Self efficacy
- Type 1 diabetes Nutritional, Metabolic, Endocrine Insulin-dependent diabetes mellitus
- United Kingdom
- 2007-06-07
Not Recruiting
- Implementing and evaluating a structured education programme and a new model of ongoing care for type 1 diabetes: the Irish Dose Adjustment For Normal Eating (DAFNE) study
- Type 1 diabetes Nutritional, Metabolic, Endocrine Insulin-dependent diabetes mellitus
- Ireland
- 2007-02-09
Not Recruiting
- Advantage of using Glucophage® SR (a Metofrmin) in non-overweight patients with type-1 Diabetes to improve their glucose control
- Type 1 diabetes Nutritional, Metabolic, Endocrine Insulin dependent diabetes mellitus
- United Kingdom
- 2010-09-17
Not recruiting
- Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
- Advanced Solid Tumors;Chronic Lymphocytic Leukemia;Advanced Solid Tumors;Chronic Lymphocytic Leukemia;Advanced Solid Tumors;Chronic Lymphocytic Leukemia
- Germany
- 2014-12-10
Not Recruiting
- Phase I study of S 78454 in the treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome
- Acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome. Cancer Acute myeloid leukemia
- France
- 2013-12-09
Not recruiting
- Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Locally Advanced or Metastatic Breast Cancer;Locally Advanced or Metastatic Breast Cancer;Locally Advanced or Metastatic Breast Cancer;Locally Advanced or Metastatic Breast Cancer
- Australia, Italy, United States
- 2008-03-05
Not Recruiting
- A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Germany, United Kingdom, United States
- 2012-10-31
Not recruiting
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
- Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1
- Belgium, Brazil, Canada, Croatia, Czech Republic, India, Israel, Macedonia, The Former Yugoslav Republic of, Poland, Russian Federation, Serbia, Slovenia, South Africa, Spain, United States
- 2013-04-16
Not Recruiting
- Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.
- Relapsing-remitting multiple sclerosis (RR MS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Belgium, Brazil, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Mexico, Slovakia, Spain, United Kingdom
- 2015-08-06
Not recruiting
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Type1 Diabetes Mellitus;Type1 Diabetes Mellitus;Type1 Diabetes Mellitus;Type1 Diabetes Mellitus
- Germany
- 2016-09-20
Not recruiting
- A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
- Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma;Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma;Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma;Hodgkin Lymphoma;Anaplastic Large-cell Lymphoma
- Belgium, Lithuania, Spain
- 2013-09-23
Not Recruiting
- Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND
- Marfan Syndrome MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
- Italy
- 2008-03-17
Not Recruiting
- A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
- Type 1 Diabetes Mellitus br>MedDRA version: 9.1 Level: LLT Classification code 10045238 Term: Type I diabetes mellitus without mention of complication
- Germany
- 2009-04-21
Not Recruiting
- Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administration of SKP-1052 versus immediate-release terbutaline and placebo tablets in stable Type 1 Diabetes Mellitus Patients
- Type 1 Diabetes Mellitus br>MedDRA version: 12.1 Level: LLT Classification code 10012601 Term: Diabetes mellitus MedDRA version: 12.1 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent MedDRA version: 12.1 Level: LLT Classification code 10012610 Term: Diabetes mellitus loss of control
- Germany
- 2010-12-08
Not Recruiting
- Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotoxic therapy - BI 6727 randomised phase II trial in ovarian cancer
- Recurrent ovarian cancer resistant or refractory to platinum compounds
- Belgium, France, Slovakia, Spain, Sweden
- 2010-02-01
Not Recruiting
- A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
- Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC) MedDRA version: 8.1 Level: LLT Classification code 10008448 Term: Chemotherapy induced emesis prophylaxis
- Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Spain, United Kingdom
- 2006-05-08
Not Recruiting
- A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects
- Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
- Germany, Hungary, Spain
- 2005-03-25
Not Recruiting
- A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV - N/A
- Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
- Czech Republic, Finland
- 2004-11-11
Not recruiting
- Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- Small Cell Lung Cancer
- Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2017-02-20